Halozyme Therapeutics Inc. has entered a global collaboration and license agreement with Chugai Pharmaceutical Co. Ltd. that gives exclusive access to Halozyme’s Enhanze drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for an undisclosed target. Chugai intends to explore the potential use of Enhanze for a Chugai drug candidate.   Under the terms of the agreement, Chugai will make an upfront payment of $25 million to Halozyme and is obligated to make potent...